title: Clinical Effects and Safety of 3% Diquafosol Ophthalmic Solution for Patients With Dry Eye After Cataract Surgery: A Randomized Controlled Trial.
abstract: OBJECTIVE
  To compare the efficacies and safety profiles of 3% diquafosol and 0.1% sodium hyaluronate in patients with dry eye after cataract surgery.
  
  
  METHODS
  Randomized controlled trial.
  
  
  METHODS
  setting: Soonchunhyang University Hospital, Seoul, South Korea.
  
  
  METHODS
  In all, 130 eyes of 86 dry eye patients who had undergone cataract surgery between January 2014 and January 2015 were enrolled and randomly divided into a diquafosol group and a sodium hyaluronate group.
  
  
  METHODS
  The diquafosol group used diquafosol 6 times a day and the hyaluronate group used sodium hyaluronate 6 times a day after cataract surgery.
  
  
  METHODS
  Evaluations of efficacy were conducted based on an Ocular Surface Disease Index questionnaire, tear breakup time (TBUT), Schirmer I test, corneal fluorescein and conjunctival lissamine green staining scores, serial measurement of ocular higher-order aberrations (HOAs), corneal HOAs, and uncorrected distance visual acuity test. Safety evaluations were based on anterior chamber inflammation and discontinuation of the eye drops.
  
  
  RESULTS
  Objective signs and subjective symptoms were aggravated at 1 week postoperatively and began to recover significantly 4 weeks after surgery. The diquafosol group showed significantly superior TBUT (P < .001), corneal fluorescein (P = .045), and conjunctival staining (P = .001) compared to the sodium hyaluronate group throughout the study period. TBUT (P < .001) and the change in HOAs (P = .018) recovered significantly more quickly in the diquafosol group. The safety evaluations showed no intergroup differences.
  
  
  CONCLUSIONS
  Eye drops of 3% diquafosol may be an effective and safe treatment for the management of cataract surgery-induced dry eye aggravation in patients with preexisting dry eye.
authors.affiliation: Department of Ophthalmology, Soonchunhyang University College of Medicine, Soonchunhyang University Hospital, Seoul, South Korea.
authors.forename: Dae Hyun
authors.initials: DH
authors.lastname: Park
authors.affiliation: Department of Ophthalmology, Soonchunhyang University College of Medicine, Soonchunhyang University Hospital, Seoul, South Korea. Electronic address: schcornea@schmc.ac.kr.
authors.forename: Jin Kwon
authors.initials: JK
authors.lastname: Chung
authors.affiliation: Department of Ophthalmology, Soonchunhyang University College of Medicine, Soonchunhyang University Hospital, Seoul, South Korea.
authors.forename: Du Ri
authors.initials: DR
authors.lastname: Seo
authors.affiliation: Department of Ophthalmology, Soonchunhyang University College of Medicine, Soonchunhyang University Hospital, Seoul, South Korea.
authors.forename: Sung Jin
authors.initials: SJ
authors.lastname: Lee
mesh_terms: D000287:Administration, Topical; D000368:Aged; D015352:Dry Eye Syndromes / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D019793:Fluorescein / Q000008:administration & dosage; D005456:Fluorescent Dyes / Q000008:administration & dosage; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D019654:Lens Implantation, Intraocular; D008086:Lissamine Green Dyes / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D018918:Phacoemulsification / Q000009:adverse effects*; D011122:Polyphosphates / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D058912:Purinergic P2Y Receptor Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D013194:Staining and Labeling / Q000379:methods; D011795:Surveys and Questionnaires; D013666:Tears / Q000737:chemistry / Q000502:physiology; D014500:Uracil Nucleotides / Q000008:administration & dosage* / Q000009:adverse effects; D055675:Viscosupplements / Q000008:administration & dosage* / Q000009:adverse effects; D014792:Visual Acuity
chemical_list: D005456:Fluorescent Dyes; D008086:Lissamine Green Dyes; D009883:Ophthalmic Solutions; D011122:Polyphosphates; D058912:Purinergic P2Y Receptor Agonists; D014500:Uracil Nucleotides; D055675:Viscosupplements; C403315:diquafosol; D006820:Hyaluronic Acid; D019793:Fluorescein